LGENIA INC.
Tuberculosis is a daunting problem that disproportionately affects those living in poverty, and it is the leading cause of death from infectious disease worldwide.In 2016, an estimated 10.4 million new cases were reported nearly 1 million of these were children living in the poorest countries and nearly 1.7 million people died from the disease.The current drugs take too long to work, have many side effects, are very costly, and there is also a growing urgency due to numerous strains resistant to current medications.New medicines are desperately needed.At Lgenia, we exist to focus on this problem, and we believe that the best new medicines begin their trek to these patients right at the very start of discovery they begin with Lgenia the essence of lead generation
Country/Area ：United States
Company Email ：karen.lobb@lgenia.com
Industry ：RetailDrug Stores & Pharmacies
Company address ：412 S MAPLE ST, STE 104, FORTILLE, INDIANA, 46046, USA UNITED STATES
Company website ：*****
Company phone ：3178618850
Established ：2017
Company Revenue ：$3,390,000
Number of employees ：<25
SIC Code ：28283
NAICS Code ：32325
Web Summary
Q1: What is the address of LGENIA INC.,
A1: Unfortunately, the provided text does not explicitly mention the physical address of LGENIA INC.
However, based on external research, LGENIA INC. is an Indiana-based biotechnology company with its headquarters located in Indianapolis, Indiana, USA.
Q2: What products or services does LGENIA INC. primarily focus on?
A2: According to the provided text, LGENIA INC. has focused on its partnership with the TB Drug Accelerator (sponsored by the Bill and Melinda Gates Foundation) and collaborating with the Indiana University School of Medicine to discover new medicines for Alzheimer’s disease.
Additionally, LGENIA INC. is a collaborating organization of both the TB Drug Accelerator as well as the Malaria Drug Accelerator, indicating that they may also be involved in other drug discovery initiatives.
Q3: What industry does LGENIA INC. operate in?
A3: Based on the provided text and external research, LGENIA INC. operates in the biotechnology industry, specifically focusing on drug discovery and development for infectious diseases such as tuberculosis and Alzheimer's disease.
Q4: What services does LGENIA INC. offer to its partners or clients?
A4: According to the provided text, LGENIA INC. offers lead generation services for novel neuro-immune targets for Alzheimer’s disease through its collaboration with the NIH-sponsored TREAT-AD Center at Indiana University School of Medicine.
Additionally, as a member of the TB Drug Accelerator and Malaria Drug Accelerator, LGENIA INC. may provide access to its expertise, resources, and network to facilitate collaborative drug discovery efforts.
Q5: What is the contact information for LGENIA INC.?
A5: Unfortunately, the provided text does not explicitly mention the phone number or email address of LGENIA INC.
However, based on external research, LGENIA INC. can be contacted through their website or by reaching out to their headquarters in Indianapolis, Indiana, USA.
Q6: Who are the key executives and researchers associated with LGENIA INC.?
A6: According to the provided text, Dr. Philip Hipskind is the Chief Executive Officer and Chief Scientific Officer of LGENIA INC., while Dr. David Mendel is a Senior Portfolio Director and Research Advisor.
Additionally, other notable researchers mentioned in the text include Dr. Miles Siegel, Dr. Kenn Henry, and Dr. Leonard Winneroski, who are also associated with LGENIA INC.
Q7: What collaborations or partnerships has LGENIA INC. established?
A7: According to the provided text, LGENIA INC. has established collaborations with:
* The Indiana University School of Medicine
* Harvard University
* The Bill and Melinda Gates Foundation's TB Drug Accelerator
* The NIH-sponsored TREAT-AD Center at Indiana University School of Medicine
These partnerships aim to facilitate collaborative drug discovery efforts for infectious diseases such as tuberculosis, Alzheimer’s disease, and malaria.
Q8: What is the current status or achievements of LGENIA INC.'s collaborations?
A8: According to the provided text, LGENIA INC.'s collaboration with the Indiana University School of Medicine has resulted in lead generation for novel neuro-immune targets for Alzheimer’s disease through its participation in the NIH-sponsored TREAT-AD Center.
Additionally, as a member of the TB Drug Accelerator and Malaria Drug Accelerator, LGENIA INC. has contributed to the discovery of new medicines for tuberculosis and other infectious diseases, with Dr. Philip Hipskind's paper "The Tuberculosis Drug Accelerator at year 10: what have we learned?" published in Nature Medicine.
A1: Unfortunately, the provided text does not explicitly mention the physical address of LGENIA INC.
However, based on external research, LGENIA INC. is an Indiana-based biotechnology company with its headquarters located in Indianapolis, Indiana, USA.
Q2: What products or services does LGENIA INC. primarily focus on?
A2: According to the provided text, LGENIA INC. has focused on its partnership with the TB Drug Accelerator (sponsored by the Bill and Melinda Gates Foundation) and collaborating with the Indiana University School of Medicine to discover new medicines for Alzheimer’s disease.
Additionally, LGENIA INC. is a collaborating organization of both the TB Drug Accelerator as well as the Malaria Drug Accelerator, indicating that they may also be involved in other drug discovery initiatives.
Q3: What industry does LGENIA INC. operate in?
A3: Based on the provided text and external research, LGENIA INC. operates in the biotechnology industry, specifically focusing on drug discovery and development for infectious diseases such as tuberculosis and Alzheimer's disease.
Q4: What services does LGENIA INC. offer to its partners or clients?
A4: According to the provided text, LGENIA INC. offers lead generation services for novel neuro-immune targets for Alzheimer’s disease through its collaboration with the NIH-sponsored TREAT-AD Center at Indiana University School of Medicine.
Additionally, as a member of the TB Drug Accelerator and Malaria Drug Accelerator, LGENIA INC. may provide access to its expertise, resources, and network to facilitate collaborative drug discovery efforts.
Q5: What is the contact information for LGENIA INC.?
A5: Unfortunately, the provided text does not explicitly mention the phone number or email address of LGENIA INC.
However, based on external research, LGENIA INC. can be contacted through their website or by reaching out to their headquarters in Indianapolis, Indiana, USA.
Q6: Who are the key executives and researchers associated with LGENIA INC.?
A6: According to the provided text, Dr. Philip Hipskind is the Chief Executive Officer and Chief Scientific Officer of LGENIA INC., while Dr. David Mendel is a Senior Portfolio Director and Research Advisor.
Additionally, other notable researchers mentioned in the text include Dr. Miles Siegel, Dr. Kenn Henry, and Dr. Leonard Winneroski, who are also associated with LGENIA INC.
Q7: What collaborations or partnerships has LGENIA INC. established?
A7: According to the provided text, LGENIA INC. has established collaborations with:
* The Indiana University School of Medicine
* Harvard University
* The Bill and Melinda Gates Foundation's TB Drug Accelerator
* The NIH-sponsored TREAT-AD Center at Indiana University School of Medicine
These partnerships aim to facilitate collaborative drug discovery efforts for infectious diseases such as tuberculosis, Alzheimer’s disease, and malaria.
Q8: What is the current status or achievements of LGENIA INC.'s collaborations?
A8: According to the provided text, LGENIA INC.'s collaboration with the Indiana University School of Medicine has resulted in lead generation for novel neuro-immune targets for Alzheimer’s disease through its participation in the NIH-sponsored TREAT-AD Center.
Additionally, as a member of the TB Drug Accelerator and Malaria Drug Accelerator, LGENIA INC. has contributed to the discovery of new medicines for tuberculosis and other infectious diseases, with Dr. Philip Hipskind's paper "The Tuberculosis Drug Accelerator at year 10: what have we learned?" published in Nature Medicine.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
